Objective To evaluate the clinical efficacy of modified Angelica Fritilaria Sophorae Pill assisting transcatheter arterial chemoembolization (TACE) to treat primary liver cancer. Methods Totally 84 patients with primary liver cancer were randomized into combination treatment group (42 cases) and conventional control group (42 cases). The conventional control group received TACE treatment, the combination treatment group received modified Angelica Fritilaria Sophorae Decoction and TACE. The tumor volume, TCM syndrome score, life quality, immune function and toxicity reaction of both groups were observed. Results Clinical observation was completed with 37 patients in each group. After three courses of treatment, the objective tumor response rate was 91.9% in combination treatment group and 86.4% in conventional control group (P<0.05). The clinical symptoms (fever, abdominal pain, vomiting, fatigue) in both groups were improved (P<0.05), with significant difference between the two groups (P<0.05). After treatment, KPS scores increased (P<0.05) in combination treatment group, and the scores of combination treatment group were significantly higher than those of the conventional control group (P<0.05). After treatment, Th1 function level increased (P<0.05) in combination treatment group, and that was better than the conventional control group (P<0.05). The incidence of liver toxicity and gastrointestinal reaction in the combination treatment group was significantly lower than that in the conventional control group (P<0.05). Conclusion Modified Angelica Fritilaria Sophorae Pill can enhance the efficacy of TACE treatment to treat primary liver cancer, reduce adverse reactions, and improve life quality of patients with primary liver cancer.

Current therapies for chronic hepatitis caused by hepatitis B virus (HBV) are limited. RNA interference (RNAi) may constitute a new therapeutic strategy for various hepatitis virus infections. In this review we present the advances in inhibition of HBV by RNAi, the unresolved questions and therapeutic potential of RNAi.

Objective To observe the concentration change of 0.5% peracetic acid used as disinfectant in the indoor air. Methods KC-6D gas-sampler and ion chromatograph were employed and sampling interval time was 10-15 min, 7 samples were collected each time in both of the condition of closed and ventilated, the same experiment was repeated for 3 times. Results As the time went on, the concentration change of 0.5% peracetic acid in the indoor air increased from 6.24 mg/m3 to 20.72 mg/m3 in the condition of closed and decreased in the condition of ventilated from 6.92 mg/m3 to 3.36 mg/m3. Conclusion In a closed room of 20 m3, using 500 ml 0.5% peracetic acid, after 30 minutes of disinfection followed by 60 minutes of ventilation, the concentration of peracetic acid will be about 3.36 mg/m3 in the air of the room.

Objective To construct a subtractive cDNA library of genes differentially expressed in human lymphoma cell line Jurkat cells treated with glycyrrhizin (GL), and to clone genes associated with its immunological regulation, and to further elucidate the molecular immune mechanism of GL. Methods The mRNA was isolated from Jurkat cells treated with either GL or 0.9 percent sodium chloride as a control, then cDNA was synthesized. Suppression subtractive hybridization (SSH) method was employed to analyze the differentially expressed DNA sequence between the two groups. The cDNA was sequenced and analyzed in GenBank with Blast search after the amplification of the subtractive library by PCR. Results The amplified library contained 28 positive clones. Colony PCR analysis showed that there were 22 clones containing 200-1 000 bp inserts. Sequence analysis was performed, and the full length sequences were obtained with bioinformatics method. Altogether 11 kinds of encoding sequences were achieved, including interleukin-12, interleukin-18, and thymosin ?1, etc. Conclusions A subtractive cDNA library of genes differentially expressed in Jurkat cells treated with GL using SSH technique was constructed successfully, and it might give some new clues for the study of the immune regulation mechanism of GL.

ObjectiveTo comprehend the clinical presentation s of systemic amyloidosis in respiratory tract MethodsThe rec ords of all patients with biopsy-confirmed systemic amyloidosis admitted to our hospital between 1985 and 2003 were retrospectively reviewed All relevant info rmations of respiratory tract,such as clinical,image,and demographic,were an alyzed ResultsAmong 46 cases of systemic amyloidosis,respira tory amyloidosis was diagnosed in 37 patients (27 men and 10 men) clinically,in vovling upper respiratory tract,tracheobronchial,lung parenchyma,pleura,medi asteinal and hilar,with a mean age of 51 49 years 12 cases were confirmed by the characteristic Congo-red staining of respiratory biopsies The most common sites at presentation were lung parenchyma and pleura ConclusionsThe respiratory tract was involved in about 80 4% of patients with systemic amylodosis meaning a higher prevalence than previously reported It is necessar y to pay more attention to respiratory amyloidosis to diagnose and treat early

Objective:To detect the expression of ALDH1 and ABCG2 in the specimens from different levels of cervical lesions.Methods:Use SP immunohistochemistry to detect the expression of ALDH1 and ABCG2 in 76 cases of cervical squamous cancers,52 cases of HSIL,and 37 cases of chronic cervicitis tissues,and analyze the results.Results:①The positive expression rates of ALDH1 and ABCG2 in chronic cervicitis tissues were 5.41％ (2/37) and 8.11％ (3/37),in HSIL tissues were 23.08％ (12/52) and 28.85％ (15/52),and in cervical cancers tissues were 53.95％ (41/76) and 61.84％ (47/76),respectively.The positive expression rates in cervical cancers tissues were significantly higher than in HSIL and Cc hronic cervicitis tissues,(P ＜ 0.05).②The positive expression of ALDH1 in cervical cancer tissues had correlation with tumor grade and lymphnode metastasis (P ＜0.05),while the positive expression of ABCG2 in cervical cancer tissues had correlation with tumor grade,clinical stage and lymph-node metastasis(P ＜0.05).③The expressions of ALDH1 and ARCG2 in cervical cancer were positive relative(r =0.535,P ＜ 0.05).Conclusions:The increased expressions of ALDH1 and ABCG2 in cervical squamous cancer may play a role in the occurrence,development and metastasis of cervical squamous cell carcinoma.ALDH1 and ABCG2 may have synergistic effect in occurrence of cervical cancer.

Objective To evaluate the effects of adriamycin on QTd and QTcd of cancer patients.Methods QTd and QTcd in 30 cancer patients before and after treated by adriamycin were measured.30 cancer patients treated without adriamycin treatment as control group.Results Value of QTd and QTcd in the patients treated by adriamycin were significantly higher than that before treated by adriamycin(P

Objective To investigate the clinical application of fecal calprotectin in inflammatory bowel disease (IBD).Methods Colonoscopy took 79 patients with IBD that were diagnosed with pathology,including 47 cases of ulcerative colitis (UC) patients,32 cases of Crohn's disease (CD).Moreover,42 cases of IBD patients without abdominal pain,diarrhea and other intestinal inflammation were used as disease control group,and 34 cases of healthy people were used as healthy control group.The level of fecal calprotectin in each group was detected by enzyme-linked immunosorbent assay (ELISA).Results The positive rate of fecal Calprotectin in IBD group,disease control group and the healthy control group was 57.0％,19.0％,and 0,respectively; each positive rate in IBD group was significantly higher than the other two groups (P ＜ 0.05).The serum concentration of fecal calprotectin in IBD group [(493.86 ±204.18) μg/g] was significantly higher than the disease control group [(71.46 ± 60.51) μg/g] and the healthy control group [(36.19 ± 13.46) μg/g] (P ＜ 0.05) ; IBD active calprotection [(1015.23 ± 324.96) μg/g] was significantly higher than resting [(52.69 ±34.71) μg/g] (P ＜0.01).Conclusions Fecal calprotectin test benefits early diagnosis of IBD,and may be taken as the diagnostic index of IBD activity.It has extensively clinical value.

Objective To study the anti-proliferation and apoptosis induction effect of cisplatin combined with Astragalus on human laryngeal cancer Hep-2 cells.Methods The proliferation inhibition of cisplatin and Astragalus alone or in combination on Laryngeal cancer Hep-2cells was measured by MTT assay.Effects of cisplatin and Astragalus alone or in combination on apoptosis of Hep-2 cells were detected by flow cytometry (FCM).Western blot was used to analyze the expressions of Bcl-2 and Bax proteins.Results The inhibition ratio of proliferation of Hep-2 cells was (53.83 ± 17.12) ％ in the astragalus group,(69.12 ± 27.12)％ in the cisplatin group,and (84.55 ± 27.84)％ in the cisplatin combined with Astragalus group,and was significantly greater than the control group (0％) (t =16.87,16.67,40.90,P ＜0.01),respectively.The apoptotic ratio of Hep-2 cells was (38.2 ± 13.6)％ in the astragalus group,(67.2 ± 17.8)％ in the cisplatin group,and (86.4 ± 25.1)％] in the cisplatin combined with Astragalus group,and was significantly greater than control group (17.1 ± 1.3) ％ (t =8.11,12.77,24.92,P ＜0.05),respectively.The effect in the combination group is better than the other group (t =11.33,9.37,P ＜ 0.01).The expressions of Bcl-2 and Bax proteins were changed.Conclusions The tumor-killing effect of cisplatin on laryngeal cancer Hep-2 cells could be enhanced significantly by the combination application of astragalus by the way of regulating the expression of Bcl-2/Bax.

The paper analyzed the impact of the trial for "lump-sum prepayment practice of medical insurance" on tertiary hospitals in Shanghai initiated by Shanghai Medical Insurance Bureau since 2009. Based on the analysis, the authors recommended that the hospitals should adapt to the changes by raising quality of care, improving cost accounting, informationizing and refining medical insurance information management, as well as controlling expenses on a rational basis. These approaches will help them adapt to and promote the ongoing health reform in China.